TY - JOUR
T1 - Investigating BRCA Mutations
T2 - A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer
AU - Modena, Alessandra
AU - Iacovelli, Roberto
AU - Scarpa, Aldo
AU - Brunelli, Matteo
AU - Ciccarese, Chiara
AU - Fantinel, Emanuela
AU - Bimbatti, Davide
AU - Massari, Francesco
AU - Martignoni, Guido
AU - Tortora, Giampaolo
PY - 2016/7/11
Y1 - 2016/7/11
N2 - Despite the development of novel effective therapeutic strategies, metastatic castration-resistant prostate cancer (mCRPC) remains a disease with a lethal course and a high biological and molecular heterogeneity. To date, germline mutations in the BRCA gene represent one of the main risk factors for developing prostate cancer, with a strong association with aggressive phenotype and poor clinical outcomes. A better understanding of the genomic landscape of prostate cancer has strengthened the idea that “synthetic lethality” of this disease might be useful in cancer-drug discovery, focusing on agents such as platinum compounds and poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi). In this review, we summarize the main data available on BRCA mutations and discuss the clinical implications of these genomic aberrations in the management of prostate cancer, stressing the need to identify prognostic and predictive biomarkers and to deeply understand the mechanisms of treatment resistance, in order to maximize personalized medicine protocols and therefore clinical benefit. [MediaObject not available: see fulltext.]
AB - Despite the development of novel effective therapeutic strategies, metastatic castration-resistant prostate cancer (mCRPC) remains a disease with a lethal course and a high biological and molecular heterogeneity. To date, germline mutations in the BRCA gene represent one of the main risk factors for developing prostate cancer, with a strong association with aggressive phenotype and poor clinical outcomes. A better understanding of the genomic landscape of prostate cancer has strengthened the idea that “synthetic lethality” of this disease might be useful in cancer-drug discovery, focusing on agents such as platinum compounds and poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi). In this review, we summarize the main data available on BRCA mutations and discuss the clinical implications of these genomic aberrations in the management of prostate cancer, stressing the need to identify prognostic and predictive biomarkers and to deeply understand the mechanisms of treatment resistance, in order to maximize personalized medicine protocols and therefore clinical benefit. [MediaObject not available: see fulltext.]
UR - http://www.scopus.com/inward/record.url?scp=84978139124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978139124&partnerID=8YFLogxK
U2 - 10.1007/s11523-016-0450-9
DO - 10.1007/s11523-016-0450-9
M3 - Article
AN - SCOPUS:84978139124
SP - 1
EP - 9
JO - Targeted Oncology
JF - Targeted Oncology
SN - 1776-2596
ER -